Beijing's CoSci Med-Tech Leads $17 Million Investment in JDP Therapeutics

CoSci Med-Tech of Beijing led a $17 million Series A financing in JDP Therapeutics, a Pennsylvania company developing a novel injectable treatment for acute allergic reactions in the hospital market. JDP is ready to start a Phase III trial of JDP-205. The company believes the funding will be enough to bring JDP-205 all the way through FDA approval. CoSci will develop the drug in China and other parts of Asia, though the terms of the agreement were not disclosed. More details.... Share this with colleagues: // //